Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

RTA 744 Injection in Patients With Leptomeningeal Disease

This study has been terminated.
(Study was closed due to loss of industry sponsorship)
Reata Pharmaceuticals, Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: August 3, 2007
Last updated: May 12, 2016
Last verified: May 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2010
  Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)